CAPR Capricor Therapeutics Inc
Company Analysis
Latest News
🔴 Capricor Therapeutics is trading 6.05% down — no clear company-specific catalyst identified
Capricor Therapeutics is trading at $6.83, down 6.05%, with no clear company-specific catalyst identified for the October 16 decline. - Recent coverage...
Capricor Pops 10% on Recycled Trial Data — But Can a Conference Poster Overcome a 9-3 FDA Panel Rejection?
Shares of Capricor Therapeutics surged 10.3% to $7.27 on October 15, buoyed by renewed investor focus on clinical data presented at the World Muscle Society...
🟢 Capricor Therapeutics is trading 10% up today on HOPE-3 data at World Muscle Society congress
Capricor Therapeutics is trading 10.32% up now at $7.27 on October 15, 2026, as reports linked the advance to attention around its HOPE-3 open-label-extension...
🟢 Capricor Therapeutics is trading 5% up today amid biotech-sector strength
Capricor Therapeutics is trading at $6.93, up +5.16%, with biotech-sector strength potentially supportive; no new company-specific announcement explaining the...
🔴 Capricor Therapeutics is trading 6.5% down in pre-market amid inflation-driven risk-off pressure
Capricor Therapeutics is trading 6.47% down at $6.16 in pre-market on October 15 amid broader risk-off pressure following hotter-than-expected U.S....
🔴 Capricor Therapeutics is trading 5% down today amid biotech and broader-market weakness
Capricor Therapeutics is trading 5.09% lower at $6.53 amid biotech and broader-market weakness; no company-specific announcement explaining the decline was...
🔴 Capricor Therapeutics is trading 5% down in pre-market with no fresh company announcement identified
Capricor Therapeutics is trading 5.43% lower at $6.51 in pre-market on October 14, with no fresh company announcement identified to explain the move. - It...
🔴 Capricor Therapeutics is trading 5% down with no confirmed fresh catalyst
Capricor Therapeutics is trading 5.22% lower at $7.08, with no confirmed company announcement explaining the decline on October 13. - The biotech sector is...
Capricor’s Positive DMD Data Leads Oppenheimer to Reaffirm $54 Target
After Capricor Therapeutics’ October 7 webinar on new positive data for its Duchenne muscular dystrophy (DMD) treatment deramiocel, Oppenheimer reiterated its...
🟢 Capricor Therapeutics is trading 5.67% up with no clear catalyst identified
Capricor Therapeutics is trading at $8.19, up 5.67%, with no clear company-specific catalyst identified. - The company’s October 5 announcement reported...
🔴 Capricor Therapeutics is trading 10% down — reason for decline remains unclear
Capricor Therapeutics is trading 10% down at $8.05; the specific reason for the decline remains unclear. - On October 5, the company announced positive HOPE-3...
🔴 Capricor Therapeutics is trading 6.2% down; specific catalyst remains unclear
Capricor Therapeutics is trading 6.2% lower at $8.40, and the specific catalyst remains unclear. - No confirmed company-specific announcement or report on...
🔴 Capricor Therapeutics is trading 5.7% down
Capricor Therapeutics is trading at $8.94, down 5.65%, in an October 1 decline with no clear catalyst identified in available coverage. - The latest reported...
Capricor Surges 24% on Fresh Duchenne Data, but Can Extension Results Overcome a 9-3 FDA Panel Rejection?
Shares of Capricor Therapeutics jumped +23.8% to $10.61 after new long-term clinical data showed that patients with Duchenne muscular dystrophy (DMD) — a...
🟢 Capricor Therapeutics is trading 23.1% up today after HOPE-3 extension data showed slower upper-limb decline
Capricor Therapeutics is trading 23.1% higher at $10.55 after HOPE-3 extension findings reported slower upper-limb and elbow-function decline among patients...
🟢 Capricor Therapeutics is trading 23.8% up in pre-market after HOPE-3 data showed slower upper-limb decline
Capricor Therapeutics is trading at $10.61, up +23.80%, after reports of HOPE-3 extension findings showing slower upper-limb and elbow-function decline among...
🟢 Capricor Therapeutics is trading 10.3% up in after-hours trading, with no clear catalyst identified
Capricor Therapeutics is trading at $9.45, up 10.27% after hours, with no clear company-specific catalyst identified. - The company is scheduled to present...
🟢 Capricor Therapeutics is trading 8% up in after-hours trading with no clear company-specific catalyst identified
Capricor Therapeutics is trading at $9.24, up 7.82%, in after-hours trading, with no clear company-specific catalyst identified for the September 29 rise. -...
🟢 Capricor Therapeutics is trading 5% up today
Capricor Therapeutics is trading 5.14% higher at $8.79, with no clear company-specific catalyst identified. - Broader U.S. markets were lower on September 28,...
🔴 Capricor Therapeutics is trading 6% down today as broad-market risk aversion likely weighs
Capricor Therapeutics is trading 6% lower at $8.78, with broad-market risk aversion the likelier immediate pressure. - A September 23 securities-fraud lawsuit...